MiNK Therapeutics INKT Institutional Ownership

Updated Oct 10, 2026

MiNK Therapeutics, Inc. (NASDAQ:INKT) counted 28 institutional investors among its 13F-reported shareholders for the quarter ended June 30, 2026.

• These investors held 4.01% of outstanding shares in Q2 2026, up from 2.55% the quarter before.
• Total holdings of MiNK Therapeutics shares rose 61.19% from Q1 2026, and the number of holders rose 55.56% from Q2 2025.
• Of these 28 holders, 14 added to their positions, 3 reduced their stakes and 11 left their positions unchanged.
• In total, institutional investors held 204.45K shares of MiNK Therapeutics at the end of Q2 2026, up 77.61K from the prior quarter and up 142.55K from a year earlier.
• Vanguard Capital Management LLC held the largest position in INKT at 68.66K shares as of June 30, 2026, or 1.35% of shares outstanding.
• Among existing holders, the largest additions to MiNK Therapeutics in Q2 2026 came from Vanguard Capital Management LLC (+9.3K shares), BlackRock, Inc. (+7.18K shares), Tower Research Capital LLC (+266 shares), Osaic Holdings, Inc. (+116 shares) and Morgan Stanley (+9 shares).
• On the other side, among holders that kept a position in MiNK Therapeutics, the largest reductions in Q2 2026 came from UBS Group AG (-10.32K shares), Geode Capital Management, LLC (-1.77K shares) and BNP Paribas Financial Markets (-3 shares).
• Business Quant data shows the 10 biggest positions in MiNK Therapeutics as of Q2 2026 were held by Vanguard Capital Management LLC (68.66K shares), DnB Asset Management AS (55.14K shares), Longbow Finance SA (16.67K shares), Geode Capital Management, LLC (15.57K shares), Citadel Advisors LLC (15.44K shares), BlackRock, Inc. (13.38K shares), Vanguard Fiduciary Trust Co (8.29K shares), UBS Group AG (4.88K shares), Steward Partners Investment Advisory, LLC (2K shares) and Us Bancorp De (2K shares).